{Reference Type}: Journal Article
{Title}: Revisiting intrathecal thiotepa: Efficacy and safety in secondary CNS malignancies.
{Author}: Jamison T;Haque E;Muhsen IN;Samarkandi H;Fakih RE;Aljurf M;
{Journal}: Med Oncol
{Volume}: 41
{Issue}: 7
{Year}: 2024 Jun 17
{Factor}: 3.738
{DOI}: 10.1007/s12032-024-02401-w
{Abstract}: Treating metastatic malignancies to the central nervous system (CNS) is challenging because many drugs cannot cross the blood-brain-barrier (BBB). Direct intrathecal (IT) drug administration into the cerebrospinal fluid (CSF) is a strategy to overcome this problem. Thiotepa has effective CNS penetration but its popularity has waned over the last two decades due to concerns about its efficacy and potential systemic toxicity. This review evaluates the available evidence for the use of IT thiotepa in hematologic malignancies and non-CNS solid tumors with leptomeningeal disease metastases (LMD). Our search shows that IT thiotepa is a reasonable alternative in hematologic malignancies and LMD due to solid organ malignancies. This suggests a potential role of IT thiotepa in second-or third-line treatment or a substitute role in cases of drug-shortages and adverse effects with other agents. Future research should focus on rigorous comparative trials to establish its definitive role in the evolving landscape of CNS-directed chemotherapy.